Source: Pediatric Rheumatology. Unidades: FM, FMRP
Subjects: VACINAS, IMUNOGENICIDADE DA VACINA, PAPILLOMAVIRUS, DOENÇAS AUTOIMUNES, SÍNDROME DE IMUNODEFICIÊNCIA ADQUIRIDA, SEGURANÇA DO PACIENTE
ABNT
GREIN, Ingrid Herta Rotstein et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study. Pediatric Rheumatology, v. 18, p. 1-12, 2020Tradução . . Disponível em: https://doi.org/10.1186/s12969-020-00479-w. Acesso em: 02 nov. 2024.APA
Grein, I. H. R., Pinto, N. B. F., Groot, N., Martins, C. B., Lobo, A., Aikawa, N. E., et al. (2020). Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study. Pediatric Rheumatology, 18, 1-12. doi:10.1186/s12969-020-00479-wNLM
Grein IHR, Pinto NBF, Groot N, Martins CB, Lobo A, Aikawa NE, Barbosa C, Terreri MT, Fraga ACM da, Oliveira SKF de, Sztajnbok F, Marques LBP, Islabão AG, Appenzeller S, Bica B, Sato J de O, Magalhães CS, Ferriani VPL, Pasmans H, Schepp R, Klis F van der, Roock S de, Wulffraat N, Pileggi GS. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study [Internet]. Pediatric Rheumatology. 2020 ; 18 1-12.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1186/s12969-020-00479-wVancouver
Grein IHR, Pinto NBF, Groot N, Martins CB, Lobo A, Aikawa NE, Barbosa C, Terreri MT, Fraga ACM da, Oliveira SKF de, Sztajnbok F, Marques LBP, Islabão AG, Appenzeller S, Bica B, Sato J de O, Magalhães CS, Ferriani VPL, Pasmans H, Schepp R, Klis F van der, Roock S de, Wulffraat N, Pileggi GS. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study [Internet]. Pediatric Rheumatology. 2020 ; 18 1-12.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1186/s12969-020-00479-w